Mary Reumuth
Director of Finance/CFO chez KALA BIO, INC.
Fortune : 582 211 $ au 31/03/2024
Profil
Mary E.
Reumuth is currently an Independent Director at Olink Holding AB since 2022 and the Chief Financial & Accounting Officer at KALA BIO, Inc. since 2014.
Previously, she worked as a Finance Director at Verenium Corp.
from 2007 to 2011, an Auditor at Ernst & Young LLP, a Manager-External Financial Reporting at Genzyme Corp., and a Controller at Enobia Pharma, Inc. from 2011 to 2012.
Ms. Reumuth obtained her undergraduate degree from Texas A&M University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KALA BIO, INC.
2,46% | 04/01/2024 | 66 136 ( 2,46% ) | 527 104 $ | 31/03/2024 |
OLINK HOLDING AB
0,00% | 05/02/2024 | 2 344 ( 0,00% ) | 55 107 $ | 31/03/2024 |
Postes actifs de Mary Reumuth
| Sociétés | Poste | Début |
|---|---|---|
| KALA BIO, INC. | Director of Finance/CFO | 01/02/2014 |
| OLINK HOLDING AB | Director/Board Member | 07/04/2022 |
Anciens postes connus de Mary Reumuth
| Sociétés | Poste | Fin |
|---|---|---|
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Comptroller/Controller/Auditor | 01/06/2012 |
| VERENIUM CORP | Director of Finance/CFO | 01/03/2011 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Mary Reumuth
| Texas A&M University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KALA BIO, INC. | Health Technology |
| OLINK HOLDING AB | Health Technology |
| Entreprise privées | 4 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Verenium Corp.
 Verenium Corp. BiotechnologyHealth Technology Verenium Corp. produces cellulosic ethanol derived from multiple biomass feedstocks. It manufactures and markets enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes such as pulp and paper and textiles. The company was founded in December 1992 and is headquartered in San Diego, CA. | Health Technology |
